Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 7;12(24):7557.
doi: 10.3390/jcm12247557.

Predictive Factors of Response to Streptozotocin in Neuroendocrine Pancreatic Neoplasms

Giuseppe Fanciulli  1 , Anna La Salvia  2 , Sergio Di Molfetta  3 , Giuseppe Cannavale  4 , Giulia Puliani  5 , Monica Verrico  6 , Federica Campolo  7 , Annamaria Colao  8 , Antongiulio Faggiano  9 , Nike Group
Affiliations
Review

Predictive Factors of Response to Streptozotocin in Neuroendocrine Pancreatic Neoplasms

Giuseppe Fanciulli et al. J Clin Med. .

Abstract

Pancreatic neuroendocrine neoplasms (Pan-NENs) may exhibit a heterogeneous clinical course, ranging from indolent to progressive/metastatic behavior. In the latter scenario, streptozocin (STZ) is considered the cornerstone of systemic treatment; however, response to STZ-based chemotherapy may vary among individuals. In this narrative review, we aimed to identify the predictive factors of response to STZ in advanced Pan-NENs. We performed an extensive search in international online databases for published studies and ongoing clinical trials evaluating STZ in Pan-NENs. We found 11 pertinent studies evaluating 17 patient-, tumor-, or treatment-related factors. Age, CgA blood levels, tumor grade, Ki-67% index, anatomical location of the primary tumor, tumor stage, site of metastasis origin, liver tumor burden, extrahepatic spread, functional status, O6-methylguanine-methyltransferase (MGMT) status, line of therapy, and response to previous treatments were all statistically associated with radiological response and/or survival. The identified predictors may help clinicians make appropriate treatment decisions, in this way improving clinical outcomes in patients with advanced Pan-NENs.

Keywords: neuroendocrine pancreatic neoplasm; predictors of response; streptozotocin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Predictors of response (ORR) to STZ in Pan-NENs. Abbreviations: CgA, Chromogranin A; DOX, doxorubicin; ORR, objective response rate; Pan-NENs, pancreatic neuroendocrine neoplasms; PS, performance status; STZ, Streptozotocin; 5-FU, 5-fluorouracil.
See this image and copyright information in PMC

References

    1. Konukiewitz B., Jesinghaus M., Kasajima A., Klöppel G. Neuroendocrine neoplasms of the pancreas: Diagnosis and pitfalls. Virchows Arch. 2022;480:247–257. doi: 10.1007/s00428-021-03211-5. - DOI - PMC - PubMed
    1. Jensen R.T., Bodei L., Capdevila J., Couvelard A., Falconi M., Glasberg S., Kloppel G., Lamberts S., Peeters M., Rindi G., et al. Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms. Neuroendocrinology. 2019;108:26–36. doi: 10.1159/000494258. - DOI - PubMed
    1. Ma Z.Y., Gong Y.F., Zhuang H.K., Zhou Z.X., Huang S.Z., Zou Y.P., Huang B.W., Sun Z.H., Zhang C.Z., Tang Y.Q., et al. Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management. World J. Gastroenterol. 2020;26:2305–2322. doi: 10.3748/wjg.v26.i19.2305. - DOI - PMC - PubMed
    1. Rindi G., Mete O., Uccella S., Basturk O., La Rosa S., Brosens L.A.A., Ezzat S., de Herder W.W., Klimstra D.S., Papotti M., et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr. Pathol. 2022;33:115–154. doi: 10.1007/s12022-022-09708-2. - DOI - PubMed
    1. Falconi M., Eriksson B., Kaltsas G., Bartsch D.K., Capdevila J., Caplin M., Kos-Kudla B., Kwekkeboom D., Rindi G., Klöppel G., et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103:153–171. doi: 10.1159/000443171. - DOI - PMC - PubMed